Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 4/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43344 | 0.89 | DRD2 (0.66) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL4067518 | 0.87 | DRD2 (0.64) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL18762842 | 0.86 | SIGMAR1 (0.61) | DRD3DRD1OPRM1TAAR1CHRM2 | |
| SCHEMBL31674607 | 0.82 | DRD2 (0.68) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL28368586 | 0.82 | DRD2 (0.68) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL11232474 | 0.82 | DRD2 (0.68) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL9670825 | 0.80 | SIGMAR1 (0.70) | TAAR1SIGMAR1 | |
| SCHEMBL8398287 | 0.80 | MGLL (0.68) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21002079 | 0.80 | MGLL (0.68) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL26548204 | 0.80 | MGLL (0.68) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728280-B1 | METHOD FOR IMPROVING THE ORAL BIOAVAILABILITY OF A DRUG | PHARMACYTICS B V (NL) | 2023-06-28 | — | — | EP | disclosed |
| EP-3995492-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3319941-B1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9663468-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663468-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3170494-A2 | TAPENTADOL COMPOSITIONS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| WO-2017011231-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160096806-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-07 | — | — | US | disclosed |
| US-9212144-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212144-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150210644-A1 | 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION | NORTHWESTERN UNIVERSITY | 2015-07-30 | — | — | US | disclosed |
| US-20150210644-A1 | 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION | NORTHWESTERN UNIVERSITY | 2015-07-30 | — | — | US | disclosed |
| CN-104211632-A | 2-Indolone derivative with tyrosine kinase inhibition activity, and preparation method and application thereof | INST RADIATION MED AMMS PLA | 2014-12-17 | — | — | CN | disclosed |
| US-RE39593-E1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects | GRUENENTHAL GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-6344558-B1 | ANALGESICS | GRUENTHAL GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | GRUENENTHAL GMBH | 2002-01-24 | — | — | US | disclosed |
| US-6248737-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | OPRM1, OPRK1, OPRD1 | DRD2 677/4885DRD3 674/4885DRD1 817/4885 |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | DRD2 1055/4885DRD3 2240/4885DRD1 1621/4885 |
| US-20150210644-A1 | 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION | NOS2, NOS3, NOS1 | DRD2 1055/4885DRD3 2240/4885DRD1 1621/4885 |
| US-20160096806-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | DRD2 1055/4885DRD3 2240/4885DRD1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.